BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 31417550)

  • 1. Examining Peripheral and Tumor Cellular Immunome in Patients With Cancer.
    Holl EK; Frazier VN; Landa K; Beasley GM; Hwang ES; Nair SK
    Front Immunol; 2019; 10():1767. PubMed ID: 31417550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a Modular Assay for Detailed Immunophenotyping of Peripheral Human Whole Blood Samples by Multicolor Flow Cytometry.
    Rühle PF; Fietkau R; Gaipl US; Frey B
    Int J Mol Sci; 2016 Aug; 17(8):. PubMed ID: 27529227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemerin Suppresses Breast Cancer Growth by Recruiting Immune Effector Cells Into the Tumor Microenvironment.
    Pachynski RK; Wang P; Salazar N; Zheng Y; Nease L; Rosalez J; Leong WI; Virdi G; Rennier K; Shin WJ; Nguyen V; Butcher EC; Zabel BA
    Front Immunol; 2019; 10():983. PubMed ID: 31139180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autologous Immune Enhancement Therapy for Cancer - Our experience since 2004.
    Terunuma H
    J Stem Cells Regen Med; 2012; 8(3):205-6. PubMed ID: 24693200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody.
    Donahue RN; Lepone LM; Grenga I; Jochems C; Fantini M; Madan RA; Heery CR; Gulley JL; Schlom J
    J Immunother Cancer; 2017; 5():20. PubMed ID: 28239472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa.
    Tsai YT; Strauss J; Toney NJ; Jochems C; Venzon DJ; Gulley JL; Schlom J; Donahue RN
    J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35418484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of circulating T-, NK-, and NKT cell subsets in patients with colorectal cancer: the peripheral blood immune cell profile.
    Krijgsman D; de Vries NL; Skovbo A; Andersen MN; Swets M; Bastiaannet E; Vahrmeijer AL; van de Velde CJH; Heemskerk MHM; Hokland M; Kuppen PJK
    Cancer Immunol Immunother; 2019 Jun; 68(6):1011-1024. PubMed ID: 31053876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New cytometry tools for immune monitoring during cancer immunotherapy.
    Sanjabi S; Lear S
    Cytometry B Clin Cytom; 2021 Jan; 100(1):10-18. PubMed ID: 33432667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adoptive transfer of osteoclast-expanded natural killer cells for immunotherapy targeting cancer stem-like cells in humanized mice.
    Kozlowska AK; Kaur K; Topchyan P; Jewett A
    Cancer Immunol Immunother; 2016 Jul; 65(7):835-45. PubMed ID: 27034236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy.
    Farsaci B; Donahue RN; Grenga I; Lepone LM; Kim PS; Dempsey B; Siebert JC; Ibrahim NK; Madan RA; Heery CR; Gulley JL; Schlom J
    Cancer Immunol Res; 2016 Sep; 4(9):755-65. PubMed ID: 27485137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous DC-CIK infusions restore CD8+ cellular immunity, physical activity and improve clinical efficacy in advanced cancer patients unresponsive to conventional treatments.
    Zhao YJ; Jiang N; Song QK; Wu JP; Song YG; Zhang HM; Chen F; Zhou L; Wang XL; Zhou XN; Yang HB; Ren J; Lyerly HK
    Asian Pac J Cancer Prev; 2015; 16(6):2419-23. PubMed ID: 25824775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.
    Varker KA; Kondadasula SV; Go MR; Lesinski GB; Ghosh-Berkebile R; Lehman A; Monk JP; Olencki T; Kendra K; Carson WE
    Clin Cancer Res; 2006 Oct; 12(19):5850-8. PubMed ID: 17020993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD56
    Vujanovic L; Chuckran C; Lin Y; Ding F; Sander CA; Santos PM; Lohr J; Mashadi-Hossein A; Warren S; White A; Huang A; Kirkwood JM; Butterfield LH
    Front Immunol; 2019; 10():14. PubMed ID: 30761123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
    da Cunha A; Antoniazi Michelin M; Cândido Murta EF
    Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment.
    Gajewski TF; Corrales L; Williams J; Horton B; Sivan A; Spranger S
    Adv Exp Med Biol; 2017; 1036():19-31. PubMed ID: 29275462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune-Phenotyping and Transcriptomic Profiling of Peripheral Blood Mononuclear Cells From Patients With Breast Cancer: Identification of a 3 Gene Signature Which Predicts Relapse of Triple Negative Breast Cancer.
    Foulds GA; Vadakekolathu J; Abdel-Fatah TMA; Nagarajan D; Reeder S; Johnson C; Hood S; Moseley PM; Chan SYT; Pockley AG; Rutella S; McArdle SEB
    Front Immunol; 2018; 9():2028. PubMed ID: 30254632
    [No Abstract]   [Full Text] [Related]  

  • 17. Combination therapy targeting both innate and adaptive immunity improves survival in a pre-clinical model of ovarian cancer.
    Hartl CA; Bertschi A; Puerto RB; Andresen C; Cheney EM; Mittendorf EA; Guerriero JL; Goldberg MS
    J Immunother Cancer; 2019 Jul; 7(1):199. PubMed ID: 31362778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Overview of Advances in Cell-Based Cancer Immunotherapies Based on the Multiple Immune-Cancer Cell Interactions.
    Zhang J; Späth SS; Weissman SM; Katz SG
    Methods Mol Biol; 2020; 2097():139-171. PubMed ID: 31776925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of innate immunity in the tumor microenvironment.
    Gonzalez-Gugel E; Saxena M; Bhardwaj N
    Cancer Immunol Immunother; 2016 Oct; 65(10):1261-8. PubMed ID: 27344341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploiting dendritic cells and natural killer T cells in immunotherapy against malignancies.
    Fujii S
    Trends Immunol; 2008 May; 29(5):242-9. PubMed ID: 18372215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.